PLSE

#1608
Pulse Biosciences, Inc - Common Stock
48.7 9 USD
+0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
48.39
49.03
Intervallo Annuale
12.56
50.90
Variazione giornaliera
+2.56%
Variazione Mensile
+35.53%
Variazione di 6 mesi
+171.36%
Variazione Annuale
+168.82%
Chiusura Precedente
47.5 7
Open
48.8 3
Minimo
48.3 9
Massimo
49.0 3
Volume
184
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
PULSE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PULSE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PULSE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PULSE BIOSCIENCES, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PULSE BIOSCIENCES, INC. current report, Q2 FY2026
8-K

PULSE BIOSCIENCES, INC. current report, Q1 FY2026

Full document

Pulse Biosciences, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on March 3, 2026. The filing serves as a Regulation FD disclosure regarding the release of an updated investor presentation (Investor Deck) posted on the company's website. The company is a Delaware corporation headquartered in Miami, Florida, with common stock trading on The Nasdaq Stock Market under the symbol PLSE.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document references an attached Investor Deck (Exhibit 99.1) that contains "certain summary financial information," but the specific figures are not included in the body of this 8-K report.

Material Changes and Strategic Focus

  • Strategic Pivot: The company announced a strengthened focus on its EP cardio ablation product and clinical development.
  • Catalyst: This strategic shift follows "unprecedented clinical outcomes data" from the company's EU feasibility study.
  • Product Development: The filing highlights the development of the next-generation nPulse cardiac catheter.

Guidance, Outlook, and Risks

The Investor Deck contains forward-looking statements subject to risks and uncertainties. The company explicitly states it undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law. The information is current as of March 2026.

Investor Verification Checklist

  • Review Exhibit 99.1 (Investor Deck) for the specific summary financial information referenced but not detailed in this filing.
  • Verify the details of the "unprecedented clinical outcomes data" from the EU feasibility study mentioned as the driver for the strategic focus.
  • Assess the development timeline and regulatory pathway for the next-generation nPulse cardiac catheter.
  • Confirm the company's current cash runway and liquidity position, as these are not disclosed in the 8-K text.

Notizie